Literature DB >> 21677599

Systemic complement activation in deceased donors is associated with acute rejection after renal transplantation in the recipient.

Jeffrey Damman1, Marc A Seelen, Cyril Moers, Mohamed R Daha, Axel Rahmel, Henri G Leuvenink, Andreas Paul, Jacques Pirenne, Rutger J Ploeg.   

Abstract

BACKGROUND: Acute rejection after renal transplantation has been shown to be negatively associated with long-term graft survival. Identifying donor factors that are associated with acute rejection in the recipient could help to a better understanding of the relevant underlying processes that lead to graft injury. Complement activation has been shown to be an important mediator of renal transplant related injury. In this study, we analyzed the effect of systemic complement activation in deceased donors before transplantation of their kidneys on posttransplant outcome in the recipient.
METHODS: Plasma from 232 deceased brain-dead and deceased cardiac-dead donors were analyzed for the complement activation markers C5b-9, C4d, Bb, and complement component mannan binding lectin by ELISA. The association of these parameters with posttransplant outcome in recipients was analyzed in a multivariate regression model.
RESULTS: It was found that C5b-9 level in donor plasma is associated with biopsy-proven acute rejection in the recipient during the first year after renal transplantation (P = 0.035). Both in deceased brain-dead and deceased cardiac-dead donors increased complement activation was found.
CONCLUSIONS: In conclusion, we found C5b-9 in the donor to be associated with acute rejection of renal transplants in the recipient. Whether targeting complement activation in the donor may ameliorate acute rejection in the recipient needs to be studied.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21677599     DOI: 10.1097/TP.0b013e318222c9a0

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  32 in total

Review 1.  The role of complement in the early immune response to transplantation.

Authors:  Steven H Sacks; Wuding Zhou
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

2.  New insight into the effects of heparinoids on complement inhibition by C1-inhibitor.

Authors:  F Poppelaars; J Damman; E L de Vrij; J G M Burgerhof; J Saye; M R Daha; H G Leuvenink; M E Uknis; M A J Seelen
Journal:  Clin Exp Immunol       Date:  2016-04-13       Impact factor: 4.330

3.  Targeted donor complement blockade after brain death prevents delayed graft function in a nonhuman primate model of kidney transplantation.

Authors:  Juan S Danobeitia; Tiffany J Zens; Peter J Chlebeck; Laura J Zitur; Jose A Reyes; Michael J Eerhart; Jennifer Coonen; Saverio Capuano; Anthony M D'Alessandro; Jose R Torrealba; Daniel Burguete; Kevin Brunner; Edwin Van Amersfoort; Yolanda Ponstein; Cees Van Kooten; Ewa Jankowska-Gan; William Burlingham; Jeremy Sullivan; Arjang Djamali; Myron Pozniak; Yucel Yankol; Luis A Fernandez
Journal:  Am J Transplant       Date:  2020-02-20       Impact factor: 8.086

4.  Donor pretreatment with nebulized complement C3a receptor antagonist mitigates brain-death induced immunological injury post-lung transplant.

Authors:  Qi Cheng; Kunal Patel; Biao Lei; Lindsay Rucker; D Patterson Allen; Peng Zhu; Chentha Vasu; Paulo N Martins; Martin Goddard; Satish N Nadig; Carl Atkinson
Journal:  Am J Transplant       Date:  2018-04-10       Impact factor: 8.086

5.  Donor Urinary C5a Levels Independently Correlate With Posttransplant Delayed Graft Function.

Authors:  Bernd Schröppel; Peter S Heeger; Heather Thiessen-Philbrook; Isaac E Hall; Mona D Doshi; Francis L Weng; Peter P Reese; Chirag R Parikh
Journal:  Transplantation       Date:  2019-01       Impact factor: 4.939

6.  Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts.

Authors:  Carl Atkinson; Bernhard Floerchinger; Fei Qiao; Sarah Casey; Tucker Williamson; Ellen Moseley; Serban Stoica; Martin Goddard; Xupeng Ge; Stefan G Tullius; Stephen Tomlinson
Journal:  Circulation       Date:  2013-02-26       Impact factor: 29.690

Review 7.  The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation.

Authors:  Stefan O Ciurea; Kai Cao; Marcelo Fernandez-Vina; Piyanuch Kongtim; Monzr Al Malki; Ephraim Fuchs; Leo Luznik; Xiao-Jun Huang; Fabio Ciceri; Franco Locatelli; Franco Aversa; Luca Castagna; Andrea Bacigalupo; Massimo Martelli; Didier Blaise; Rupert Handgretinger; Denis-Claude Roy; Paul O'Donnell; Asad Bashey; Hillard M Lazarus; Karen Ballen; Bipin N Savani; Mohamad Mohty; Arnon Nagler
Journal:  Bone Marrow Transplant       Date:  2018-01-15       Impact factor: 5.483

Review 8.  The renaissance of complement therapeutics.

Authors:  Daniel Ricklin; Dimitrios C Mastellos; Edimara S Reis; John D Lambris
Journal:  Nat Rev Nephrol       Date:  2017-12-04       Impact factor: 28.314

Review 9.  Applying complement therapeutics to rare diseases.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Despina Yancopoulou; Antonio M Risitano; Daniel Ricklin; John D Lambris
Journal:  Clin Immunol       Date:  2015-09-01       Impact factor: 3.969

Review 10.  The innate immune system and transplantation.

Authors:  Conrad A Farrar; Jerzy W Kupiec-Weglinski; Steven H Sacks
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.